Dry eye disease is a common ocular surface disorder among ophthalmological conditions. Treatment generally focuses on tear supplement by topical artificial tears but less focus on the immunological changes in the pathogenesis of the dry eye. As our understanding of the pathology of the disease improves, new definitions are being developed. It turns out that inflammation, and dry eye accompanied relationship can not be ignored. Topical corticosteroid therapy for dry eye should be more cautioned and topical use of Cyclosporin A (CsA) and nonsteroidal anti-inflammatory drugs (NSAIDs) require more attention. In order to standardize management strategies for dry eye, multi-center studies for the link between inflammation and dry eye are needed, and epidemiological survey should be performed.